Faulty COVID-19 Test Kits Tilt Scales in Coronavirus's Favor [The Motley Fool]
Co-Diagnostics, Inc. (CODX)
US:NASDAQ Investor Relations:
ir.codiagnostics.com/investor-relations
Company Research
Source: The Motley Fool
Faulty COVID-19 Test Kits Tilt Scales in Coronavirus's Favor Flawed coronavirus test kits from the Centers for Disease Control severely limited the number of U.S. patients screened in January and February. The U.S. government's response to the rapidly escalating coronavirus outbreak is receiving a strong dose of criticism. Instead of quickly testing every individual known to have been exposed to SARS-CoV-2, the coronavirus that causes COVID-19, just 3,600 were tested during January and February. The first misstep along the path to what could become an uncontained outbreak in this country belonged to the Centers for Disease Control. Instead of using testing kits already provided by the World Health Organization, the CDC decided to create its own. Unfortunately, there have been problems with the test kits sent out by the CDC that rendered most of them useless. The CDC didn't begin sending testing kits to hospitals until Feb. 4, which means thousands of blood samples were sent to one of
Show less
Read more
Impact Snapshot
Event Time:
CODX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CODX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CODX alerts
High impacting Co-Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
CODX
News
- Global COVID-19 Diagnostic Market Report 2024 -2029: A New Very Large and Sustainable Market for Covid Related Diagnostics is Emerging [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo FacilityPR Newswire
- Co-Diagnostics, Inc. (NASDAQ: CODX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.MarketBeat
- Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
CODX
Earnings
- 11/7/24 - Beat
CODX
Analyst Actions
- 11/11/24 - HC Wainwright
CODX
Sec Filings
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- CODX's page on the SEC website